View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
DOJ/DEA RIN: 1117-AA61 Publication ID: Spring 2011 
Title: Electronic Prescriptions for Controlled Substances 
Abstract: DEA is revising its regulations to establish the criteria that will allow DEA-registered practitioners to sign and transmit controlled substances prescriptions electronically. The regulations will also permit pharmacies to receive, dispense, and archive these electronic prescriptions. These regulations would not mandate the use of electronic prescriptions, but would establish the requirements that must be met by any registrant that wishes to issue or receive electronic prescriptions for controlled substances. The regulations would establish requirements that practitioners must meet when issuing electronic prescriptions, including requirements for the software applications used to issue those prescriptions; registrants would have to use only those software applications that meet the security requirements if they intend to sign, transmit, or process electronic prescriptions for controlled substances. The regulations would not apply to software used to create a prescription that is then printed and manually signed. These revised regulations would be in addition to, not a replacement of, the existing rules. 
Agency: Department of Justice(DOJ)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Yes  Unfunded Mandates: No 
CFR Citation: 21 CFR 1300    21 CFR 1306    21 CFR 1311   
Legal Authority: 21 USC 802    21 USC 821    21 USC 827    21 USC 829    21 USC 871(b)   
Legal Deadline:  None
Timetable:
Action Date FR Cite
ANPRM  03/05/2001  66 FR 13274   
NPRM  06/27/2008  73 FR 36722   
NPRM Comment Period End  09/25/2008    
Interim Final Rule  03/31/2010  75 FR 16236   
Interim Final Rule Comment Period End  06/01/2010    
Interim Final Rule Effective  06/01/2010    
Final Action  11/00/2011    
Additional Information: DEA-218
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Federalism: No 
Included in the Regulatory Plan: No 
Public Comment URL: www.deadiversion.usdoj.gov  
RIN Data Printed in the FR: No 
Agency Contact:
Cathy A. Gallagher
Acting Chief, Liaison and Policy Section
Department of Justice
Drug Enforcement Administration
600 Army Navy Drive,
Arlington, VA 22202
Phone:202 307-7297
Email: cathy.a.gallagher@usdoj.gov